Increased 5α-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation

[1]  Takashi Suzuki,et al.  Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. , 2010, Endocrine-related cancer.

[2]  Takashi Suzuki,et al.  Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients , 2010, Breast Cancer Research and Treatment.

[3]  Satoru Takahashi,et al.  Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer , 2009, Cancer science.

[4]  Takashi Suzuki,et al.  New Developments in Intracrinology of Human Breast Cancer , 2009, Annals of the New York Academy of Sciences.

[5]  W. Loo,et al.  Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  F. Labrie,et al.  Androgen biosynthetic pathways in the human prostate. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[7]  Takashi Suzuki,et al.  Intracrinology of estrogens and androgens in breast carcinoma , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  Yate-Ching Yuan,et al.  New experimental models for aromatase inhibitor resistance , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Takashi Suzuki,et al.  5α‐Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production , 2007, International journal of cancer.

[10]  Zhiyong Guo,et al.  Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. , 2006, Cancer research.

[11]  W. Miller,et al.  Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole , 2006, British Journal of Cancer.

[12]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[13]  J. Dixon,et al.  Aromatase inhibitors: Cellular and molecular effects , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  P. Lønning,et al.  Aromatase Inhibition: Translation into a Successful Therapeutic Approach , 2005, Clinical Cancer Research.

[15]  M. Dowsett,et al.  Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Wiebe,et al.  The role of progesterone metabolites in breast cancer: Potential for new diagnostics and therapeutics , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  G. Chetrite,et al.  Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  A. Lykkesfeldt,et al.  Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  J. Wiebe,et al.  Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma , 2004, BMC Cancer.

[20]  A. Brodie,et al.  Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. , 2003, Cancer research.

[21]  P. Peeters,et al.  The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  H. Denk,et al.  Androgen receptors frequently are expressed in breast carcinomas , 2003, Cancer.

[23]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.

[24]  Takashi Suzuki,et al.  5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  H. Sasano,et al.  7β-hydroxysteroid Dehydrogenase Type 1 and Type 2 in Human Breast Carcinoma: a Correlation to Clinicopathological Parameters , 2022 .

[26]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Secreto,et al.  Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  I. Ellis,et al.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.

[29]  B. Marchetti,et al.  Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors , 1988, Breast Cancer Research and Treatment.

[30]  F. Labrie,et al.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line , 1988, Breast Cancer Research and Treatment.

[31]  M. Lippman,et al.  The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.

[32]  A. Forrest,et al.  ŒSTRADIOL SYNTHESIS BY A HUMAN BREAST CARCINOMA , 1974 .

[33]  A. Forrest,et al.  Metabolism of androgens by human breast tissue. , 1973, Lancet.

[34]  J. Geisler.  Aromatase inhibitors: from bench to bedside and back , 2008, Breast cancer.

[35]  M. Lippman,et al.  The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.

[36]  W. den Boer,et al.  Letter: Phenprocoumon-induced jaundice. , 1976, Lancet.

[37]  C. Dent.  Letter: Blood, plasma, or serum? , 1975, Lancet.

[38]  A. Forrest,et al.  Oestradiol synthesis by a human breast carcinoma. , 1974, Lancet.